← Back to Search

Behavioural Intervention

PrEP Care Anywhere Services for Patient Adherence (PCA Trial)

N/A

Waitlist Available

Led By Jason E Farley, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 3, 6 and 9 months

Awards & highlights

PCA Trial Summary

This trial is being done to learn more about the differences in engaging, recruiting, linking and adhering to pre-exposure prophylaxis (PrEP) services for men who have sex with other men at risk for HIV in Baltimore City. The study will compare a new, more patient-centered approach to the standard clinic-based PrEP services to see if it improves adherence and retention in care.

PCA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 3, 6 and 9 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 3, 6 and 9 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 3, 6 and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

PrEP Uptake

Secondary outcome measures

PrEP Adherence

Other outcome measures

PrEP Retention

PCA Trial Design

1Treatment groups

Experimental Treatment

Group I: PrEP Care Anywhere ServicesExperimental Treatment1 Intervention

The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,261 Previous Clinical Trials

14,821,048 Total Patients Enrolled

Gilead SciencesIndustry Sponsor

1,084 Previous Clinical Trials

843,459 Total Patients Enrolled

Jason E Farley, PhDPrincipal InvestigatorJohns Hopkins University School of Nursing

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research program accept participants over the age of fifty?

"This trial is open to participants aged 18-99. For minors and seniors, there are 4 separate studies for those under 18 years old, as well as 10 distinct trials designed specifically for individuals over the age of 65."

Answered by AI

What is the peak capacity of participants in this research endeavor?

"Affirmative. Clinicaltrials.gov reveals that this research, initially posted on July 30th 2018 and recently revised on December 8th 2021, is actively seeking participants. Approximately 120 individuals are required to be enrolled from one medical site."

Answered by AI

Are there any vacancies available in this clinical trial?

"Data from clinicaltrials.gov reveals that this study is still recruiting patients and was originally posted on July 30th 2018, with the most recent edit taking place on December 8 2021."

Answered by AI

What are the necessary qualifications to be eligible for this trial?

"This clinical trial seeks 120 volunteers, aged 18 to 99 years old with adherence issues. Additionally, participants should meet the following conditions: African American/Black and Latino men of color comprising up to 20% Caucasian males; Men who have had unprotected sex with a male partner within the past year; HIV-negative adults that are eligible for CDC risk criteria; Interested in pursuing Prep services virtually via an EPIC polycom platform. Furthermore, individuals must be willing to participate in study procedures (e.g., baseline and 3 month visits) as well as possess internet connectivity necessary for virtual engagement."

Answered by AI

Recent research and studies

PLoS ONEJournal

MTN-001: Randomized Pharmacokinetic Cross-over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments

Hendrix, Craig W., Beatrice A. Chen, Vijayanand Guddera, Craig Hoesley, Jessica Justman, Clemensia Nakabiito, Robert Salata, et al.. 2013. “MTN-001: Randomized Pharmacokinetic Cross-over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments”. Edited by Gilda Tachedjian. Plos ONE. Public Library of Science (PLoS). doi:10.1371/journal.pone.0055013.

International Journal for Equity in HealthJournal

Critical Race Theory as a Tool for Understanding Poor Engagement Along the HIV Care Continuum Among African American/black and Hispanic Persons Living with HIV in the United States: A Qualitative Exploration

Freeman, Robert, Marya Viorst Gwadz, Elizabeth Silverman, Alexandra Kutnick, Noelle R. Leonard, Amanda S. Ritchie, Jennifer Reed, and Belkis Y. Martinez. 2017. “Critical Race Theory as a Tool for Understanding Poor Engagement Along the HIV Care Continuum Among African American/black and Hispanic Persons Living with HIV in the United States: A Qualitative Exploration”. International Journal for Equity in Health. Springer Science and Business Media LLC. doi:10.1186/s12939-017-0549-3.

The LancetJournal

Uptake of Prep for HIV Slow Among MSM

Kirby, Tony, and Michelle Thornber-Dunwell. 2014. “Uptake of Prep for HIV Slow Among MSM”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(14)60137-9.

Culture, Health & SexualityJournal